Anal & Cervical Cancer
Anal & Cervical Cancer
IDWeek 2016: Only a Small Proportion of HIV+ Gay Men Receive Anal Cancer Screening
- Details
- Category: Cancer/Malignancies
- Published on Friday, 28 October 2016 00:00
- Written by Liz Highleyman
In the absence of national screening guidelines, only 11% of HIV-positive gay and bisexual men in the U.S. received anal Pap smears to detect anal cancer or precancerous cell changes during 2009-2012, with disparities between patient groups and variations across centers, according to a presentation at IDWeek, taking place this week in New Orleans.
ASCO 2016: PD-1 Blocker Nivolumab Shows Promise for Advanced Anal Cancer
- Details
- Category: Anal & Cervical Cancer
- Published on Monday, 06 June 2016 00:00
- Written by MD Anderson Cancer Center
The checkpoint inhibitor nivolumab(Opdivo), a monoclonal antibody targeting the PD-1 receptor, demonstrated activity against metastatic anal cancer that in patients who did not respond to prior treatment, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. 70% of participants in this small study experienced complete or partial response or stabilized disease.
WHO Recommends 2-Dose Vaccine, HPV Screening for Cervical Cancer Prevention
- Details
- Category: Anal & Cervical Cancer
- Published on Tuesday, 09 December 2014 00:00
- Written by WHO
The World Health Organization (WHO) last week released new guidance for preventing and controlling cervical cancer, which causes more than 270,000 deaths annually worldwide. The guidelines call for girls to receive 2 rather than 3 doses of the human papillomavirus (HPV) vaccine and for women to be screened using less frequent HPV tests rather than Pap smears.
CROI 2015: Screening May Miss Pre-cancerous Anal Lesions in Women with HIV
- Details
- Category: Human Papillomavirus (HPV)
- Published on Monday, 09 March 2015 00:00
- Written by Theo Smart
Existing algorithms to screen for anal cancer in women living with HIV could be missing many cases of anal high-grade squamous intraepithelial lesions (HSIL) -- abnormal tissue changes that may be a precursor to invasive anal cancer -- according to a study reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
FDA Approves New Vaccine Effective Against 9 Types of Human Papillomavirus
- Details
- Category: Anal & Cervical Cancer
- Published on Tuesday, 09 December 2014 00:00
- Written by WHO
The U.S. Food and Drug Administration this week approved a new "9-valent" human papillomavirus (HPV) vaccine from Merck that protects against infection with more high-risk or cancer-causing strains. The new Gardasil 9 vaccine is expected to prevent about 90% of cervical, anal, and genital cancers. The vaccine is approved for young women ages 9-26 and young men ages 9-15.
Web Design and Development by